Literature DB >> 17954699

Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.

Joshua S Hawley1, Clinton K Murray, James H Jorgensen.   

Abstract

Colistin heteroresistance has been reported among Acinetobacter isolates; however, its association with prior colistin therapy has not been not described. A population analysis profile identified resistant Acinetobacter subpopulations from colistin-susceptible clinical isolates. The proportion of cells exhibiting heteroresistance was significantly higher among isolates recovered from patients treated with colistin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17954699      PMCID： PMC2223915          DOI： 10.1128/AAC.00766-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

3.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.

Authors:  Joshua S Hawley; Clinton K Murray; Matthew E Griffith; M Leticia McElmeel; Letitia C Fulcher; Duane R Hospenthal; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

5.  Impact of Acinetobacter infection on the mortality of burn patients.

Authors:  Michael C Albrecht; Michael A Albrecht; Matthew E Griffith; Clinton K Murray; Kevin K Chung; Edward E Horvath; John A Ward; Duane R Hospenthal; John B Holcomb; Steven E Wolf
Journal:  J Am Coll Surg       Date:  2006-08-24       Impact factor: 6.113

6.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

7.  Multidrug-resistant Acinetobacter extremity infections in soldiers.

Authors:  Kepler A Davis; Kimberly A Moran; C Kenneth McAllister; Paula J Gray
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883
  7 in total
  68 in total

1.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

2.  Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.

Authors:  N C Gordon; K Png; D W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

3.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Authors:  Luis A Arroyo; Ingeborg Mateos; Verónica González; Javier Aznar
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium.

Authors:  Song Sun; Aurel Negrea; Mikael Rhen; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

Review 6.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Efficacy of colistin-impregnated beads to prevent multidrug-resistant A. baumannii implant-associated osteomyelitis.

Authors:  Daniel P Crane; Kirill Gromov; Dan Li; Kjeld Søballe; Christian Wahnes; Hubert Büchner; Matthew J Hilton; Regis J O'Keefe; Clinton K Murray; Edward M Schwarz
Journal:  J Orthop Res       Date:  2009-08       Impact factor: 3.494

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.

Authors:  Alina D Gutu; Nicole Sgambati; Pnina Strasbourger; Mark K Brannon; Michael A Jacobs; Eric Haugen; Rajinder K Kaul; Helle Krogh Johansen; Niels Høiby; Samuel M Moskowitz
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  An Amphipathic Undecapeptide with All d-Amino Acids Shows Promising Activity against Colistin-Resistant Strains of Acinetobacter baumannii and a Dual Mode of Action.

Authors:  Alberto Oddo; Thomas T Thomsen; Susanne Kjelstrup; Ciara Gorey; Henrik Franzyk; Niels Frimodt-Møller; Anders Løbner-Olesen; Paul R Hansen
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.